latest news releases from the newsroom
Triangle Capital Corporation
Triangle Capital Corporation Declares Cash Dividend of $0.40 Per Share
RALEIGH, N.C., Dec. 8, 2008 (GLOBE NEWSWIRE) -- Triangle Capital Corporation (Nasdaq:TCAP) ("Triangle" or the "Company"), a leading specialty finance company that provides customized financing solutions to lower middle market companies located throughout the United States, today announced that its board of directors has declared a cash dividend of $0.40 per share. This is the Company's eighth consecutive quarterly dividend since its initial public offering in February, 2007, and reflects a 33.3% increase over the same quarter in 2007.
The Korea Fund, Inc.
The Korea Fund, Inc. Reports Results for the Fiscal Quarter Ended September 30, 2008
NEW YORK, Dec. 8, 2008 (GLOBE NEWSWIRE) -- The Korea Fund, Inc. (the "Fund") (NYSE:KF), a non-diversified, closed-end investment company, which seeks long-term capital appreciation through investing primarily in equity securities trading on the Korean stock exchanges, today announced its results for the fiscal quarter ended September 30, 2008.
RedChip Companies Inc.
RedChip Visibility Issues Third Quarter 2008 Research Update On ZAGG
ORLANDO, Fla., Dec. 8, 2008 (GLOBE NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc. announced today that it has issued a third quarter 2008 research update for ZAGG, Inc. (OTCBB:ZAGG), a company that designs, manufactures and distributes protective clear coverings and accessories for consumer electronic and hand-held devices under the brand name invisibleSHIELD(tm).
Immunomedics Reports Initial Results From Phase I/II Study of Veltuzumab in Immune Thrombocytopenic Purpura
SAN FRANCISCO, Dec. 8, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that low doses of veltuzumab, administered either intravenously or subcutaneously, demonstrated promising activity, including durable complete responses, in patients with immune thrombocytopenic purpura (ITP). Results from this multicenter, open-label, single-arm Phase I/II study were presented at the 50th American Society of Hematology annual meeting.